ArticleTranslational oncology2026
A mature tertiary lymphoid structure-associated spatial niche is inversely associated with ACC1-related lipid metabolism in neoadjuvant-treated hepatocellular carcinoma.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor heterogeneity in hepatocellular carcinoma (HCC) is shaped by spatially organized immune and metabolic ecosystems that may influence therapeutic response. However, how mature tertiary lymphoid structure (TLS) niches relate to tumor metabolic heterogeneity remains poorly defined. We integrated seven 10x Visium sections from patients with locally advanced HCC treated with neoadjuvant cabozantinib plus nivolumab, a single-cell reference atlas, three independent bulk cohorts, and a pathological validation cohort of 69 HCC specimens. Reference-based deconvolution and neighborhood-composition clustering identified eleven recurrent multicellular niches, including a B-cell-, plasma-cell-, and T-cell-enriched mature TLS-associated niche (Niche5). Niche5 showed greater spatial aggregation in pathological responders, accompanied by stronger CCL21-CCR7, CXCL13-CXCR5, and CCL19-CCR7 signaling. Within Niche5, fatty-acid metabolism was inversely correlated with the TLS program (Spearman r=-0.35) and chemokine-ligand expression. A six-gene Niche5-derived signature selected using a machine-learning framework stratified overall survival across three independent cohorts. Among fatty-acid-metabolism enzymes, ACACA, encoding ACC1, showed the most reproducible negative association with TLS chemokines, antigen presentation, CD8-positive T-cell programs, and survival. Multiplex immunofluorescence and immunohistochemistry confirmed mature TLS architecture and demonstrated spatial separation between TLS and ACC1-, FABP5-, and PLIN2-enriched tumor compartments. In the validation cohort, TLS-positive tumors showed lower ACC1, FABP5, and PLIN2 expression but higher CCL21, CXCL13, and CCR7 expression, while high ACC1 expression was independently associated with reduced TLS positivity. Together, these findings provide exploratory evidence of immune-metabolic spatial heterogeneity in HCC and identify an inverse, associative relationship between mature TLS organization and ACC1-related lipid metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.